SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Myriad Genetics, Inc. (MYGN) News

Follow Myriad Genetics, Inc. (MYGN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 29 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol MYGN Asset equity Sector Markets 90 days 18 Last 5.47 Updated Nov 05, 2026, 02:18 PM UTC Open live news feed Open MYGN chart & news
M Myriad Genetics Suspends Testing After Unauthorized Network Access The company detected unauthorized access in its IT network on Nov. 2 and temporarily suspended testing operations. EQUITY | Nov 05, 2026, 02:18 PM UTC M Myriad Genetics Reports Unauthorized Network Access, Most Systems Restored Myriad Genetics detected unauthorized access to its IT network and says most systems have returned to normal operations. EQUITY | Nov 05, 2026, 02:13 PM UTC M Myriad Genetics Q3 Revenue Beats Estimates, Raises FY Guidance Myriad Genetics reported third-quarter revenue above analyst estimates and raised its fiscal-year guidance. EQUITY | Nov 04, 2026, 10:14 PM UTC M Myriad Genetics Reports 3Q Revenue of $202.7 Million EARNINGS | Nov 04, 2026, 09:11 PM UTC M Myriad Genetics Reports $43.9M Third-Quarter Loss EQUITY | Nov 04, 2026, 09:11 PM UTC M Myriad Genetics Agrees to Sell Prenatal Testing Business to Labcorp Myriad Genetics agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash plus inventory value. Myriad shares rose 22.2% in premarket trading. MNA | Oct 20, 2026, 02:21 PM UTC M Labcorp to Buy Myriad Genetics Prenatal Testing Business for $210 Million Myriad Genetics agreed to sell its prenatal health testing business to Labcorp for $210 million in cash plus the value of inventory. The business includes Prequel, Foresight, SneakPeek and FirstGene. MNA | Oct 20, 2026, 01:02 PM UTC M Myriad Genetics to Sell Prenatal Testing Business to Labcorp for $210M Myriad Genetics will receive $210 million in cash plus the value of inventory at closing. MNA | Oct 20, 2026, 12:43 PM UTC M Myriad Genetics to Sell Prenatal Testing Business to Labcorp Myriad Genetics and Labcorp announced a definitive agreement for Myriad to sell its prenatal health testing business to Labcorp. MNA | Oct 20, 2026, 12:42 PM UTC L Labcorp Expects Transaction to Add to Adjusted Earnings in Year One Labcorp expects the transaction to be slightly accretive to adjusted earnings in year one and reach average diagnostics segment margins by the end of year two, once fully integrated. MNA | Oct 20, 2026, 12:35 PM UTC M Myriad Genetics to report third-quarter 2026 results November 4 EQUITY | Oct 15, 2026, 08:05 PM UTC H Myriad Genetics Affirms FY2026 Sales Guidance of $770.000M-$790.000M vs $776.790M Est Myriad Genetics (NASDAQ: MYGN ) affirms FY2026 sales outlook from $770.000 million-$790.000 million to $770.000 million-$790.000 million vs $776.790 million estimate. LIVE | Sep 16, 2026, 12:56 PM UTC L MYGN - Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial MYGN - Myriad Genetics Appoints Vishal Sikri Executive Vice President - Commercial NEWS | Sep 16, 2026, 12:01 PM UTC L UBS keeps Myriad Genetics at neutral; price target cut UBS maintains a neutral view on Myriad Genetics and cuts its price target to $3.60 per share from $6.00, according to Benzinga ratings actions. EQUITY | Sep 09, 2026, 06:15 PM UTC L Myriad Genetics cut to underweight from overweight Myriad Genetics was cut to underweight from overweight by Piper Sandler. EQUITY | Sep 02, 2026, 09:14 AM UTC M Myriad Genetics shares fall 6.2% after Piper Sandler downgrade Myriad Genetics shares fell 6.2% in the afternoon session after Piper Sandler double-downgraded the stock to Underweight, saying major strategic action is likely needed. EQUITY | Sep 01, 2026, 06:41 PM UTC L This Biotech Stock Got a Rare Double-Downgrade. Its Profitability Problem Just Got Worse. — Barrons.com By Mackenzie TatananniAs shares of Myriad Genetics show no signs of returning to their peak from over two decades ago, one firm double-downgraded the already depressed stock, saying the company's latest earnings cast dou EARNINGS | Sep 01, 2026, 04:38 PM UTC L Myriad Genetics to present at 2026 Wells Fargo Healthcare conference Myriad Genetics says it will present at the 2026 Wells Fargo Healthcare Conference. EQUITY | Aug 27, 2026, 01:05 PM UTC H Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 200 points on Friday. The Dow traded up 0.38% to 52,406.69 while the NASDAQ rose 0.25% to 25,184.43. The S&P 500 also rose, gainin EARNINGS | Jul 31, 2026, 04:02 PM UTC H Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 300 points on Friday. Shares of Apple Inc (NASDAQ: AAPL ) fell sharply in pre-market trading after the company posted results for th EARNINGS | Jul 31, 2026, 12:03 PM UTC H US Stocks Rise After Earnings US stocks rise after earnings reports EARNINGS | Jul 31, 2026, 11:56 AM UTC H Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket Shares of Amazon.com Inc (NASDAQ: AMZN ) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the EARNINGS | Jul 31, 2026, 08:50 AM UTC L Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know Myriad Genetics Inc. (NASDAQ: MYGN ) shares plunged 37.80% in Thursday’s after-hours session after the company reported second-quarter 2026 financial results that included lower revenue, an operating loss, reduced full-y EARNINGS | Jul 31, 2026, 05:48 AM UTC L MYGN Posts Wider Q2 Loss MYGN reports wider Q2 loss EARNINGS | Jul 30, 2026, 08:46 PM UTC H MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results MYGN -29%, RBLX -11.6%, FLGT -10.7%, VCYT -9.8%, SYK -9.5%, ALHC -8.6%, COIN -6.5%, RDDT -5.8%, GSIT -5.3%, IR -3.1% after results EARNINGS | Jul 30, 2026, 08:15 PM UTC L MYGN Myriad Genetics RESULTS: Q2, Q2 REV $190.7M vs. EST $206M, Q2 operating expenses $165.9M, Q2 ADJ operating expenses $150.5M, Q2 Operati MYGN Myriad Genetics RESULTS: Q2, Q2 REV $190.7M vs. EST $206M, Q2 operating expenses $165.9M, Q2 ADJ operating expenses $150.5M, Q2 Operating Income $-38.9M, Q2 gross margin 66.6% EARNINGS | Jul 30, 2026, 08:07 PM UTC L MYGN - Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Pro MYGN - Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability EARNINGS | Jul 30, 2026, 08:06 PM UTC L Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est Myriad Genetics (NASDAQ: MYGN ) lowers FY2026 sales outlook from $860.000 million-$880.000 million to $770.000 million-$790.000 million vs $863.568 million estimate. EARNINGS | Jul 30, 2026, 08:06 PM UTC M MYGN Expands Cancer Test Myriad Genetics expands availability of Precise MRD for colorectal, renal, and breast cancers EQUITY | Jun 23, 2026, 01:05 PM UTC